[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

NO20032111D0 - New drug compositions based on tiotropium salts and on salmeterol salts - Google Patents

New drug compositions based on tiotropium salts and on salmeterol salts

Info

Publication number
NO20032111D0
NO20032111D0 NO20032111A NO20032111A NO20032111D0 NO 20032111 D0 NO20032111 D0 NO 20032111D0 NO 20032111 A NO20032111 A NO 20032111A NO 20032111 A NO20032111 A NO 20032111A NO 20032111 D0 NO20032111 D0 NO 20032111D0
Authority
NO
Norway
Prior art keywords
salts
salmeterol
drug compositions
tiotropium
new drug
Prior art date
Application number
NO20032111A
Other languages
Norwegian (no)
Other versions
NO20032111L (en
Inventor
Juergen Nagel
Christel Schmelzer
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of NO20032111D0 publication Critical patent/NO20032111D0/en
Publication of NO20032111L publication Critical patent/NO20032111L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Drug compositions containing one or more tiotropium salts and one or more salmeterol salts, are new. Drug compositions containing one or more tiotropium salts and one or more salmeterol salts, are new. The salts can be present in the form of enantiomers, enantiomer mixtures or racemates as well as in the form of solvates or hydrates. The compositions may also contain a pharmaceutical adjuvant. ACTIVITY : Antiasthmatic. MECHANISM OF ACTION : Anticholinergic; beta -mimetic.
NO20032111A 2000-11-13 2003-05-12 New drug mixtures based on tiotropium salts and on salmeterol salts NO20032111L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10056104A DE10056104A1 (en) 2000-11-13 2000-11-13 Drug compositions useful for treatment of respiratory diseases, especially asthma and chronic obstructive pulmonary disease comprises tiotropium salts and salmeterol salts
PCT/EP2001/012962 WO2002038154A1 (en) 2000-11-13 2001-11-09 Novel medicament compositions based on tiotropium salts and on salmeterol salts

Publications (2)

Publication Number Publication Date
NO20032111D0 true NO20032111D0 (en) 2003-05-12
NO20032111L NO20032111L (en) 2003-07-08

Family

ID=7663071

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20032111A NO20032111L (en) 2000-11-13 2003-05-12 New drug mixtures based on tiotropium salts and on salmeterol salts

Country Status (32)

Country Link
EP (3) EP1335728B1 (en)
JP (2) JP4282322B2 (en)
KR (2) KR100940752B1 (en)
CN (1) CN1678318A (en)
AT (2) ATE291428T1 (en)
AU (3) AU2002227910B2 (en)
BG (1) BG107781A (en)
BR (1) BR0115226A (en)
CA (1) CA2429012A1 (en)
CY (1) CY1106774T1 (en)
CZ (1) CZ20031444A3 (en)
DE (3) DE10056104A1 (en)
DK (2) DK1335728T3 (en)
EA (1) EA007904B1 (en)
EC (1) ECSP034571A (en)
EE (1) EE200300228A (en)
ES (2) ES2287629T3 (en)
HR (1) HRP20030378A2 (en)
HU (1) HUP0301447A3 (en)
IL (2) IL155718A0 (en)
MX (1) MXPA03004164A (en)
NO (1) NO20032111L (en)
NZ (1) NZ526400A (en)
PL (1) PL205330B1 (en)
PT (2) PT1335728E (en)
RS (2) RS20090105A (en)
SG (1) SG167657A1 (en)
SI (2) SI1514546T1 (en)
SK (2) SK286950B6 (en)
UA (1) UA74853C2 (en)
WO (1) WO2002038154A1 (en)
ZA (1) ZA200302921B (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2165768B1 (en) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa NEW DERIVATIVES OF QUINUCLIDINE AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM.
US7214687B2 (en) 1999-07-14 2007-05-08 Almirall Ag Quinuclidine derivatives and medicinal compositions containing the same
ES2234694T3 (en) * 1999-11-23 2005-07-01 Glaxo Group Limited PHARMACEUTICAL FORMULATIONS OF SALMETEROL.
MXPA04002401A (en) * 2001-09-14 2004-05-31 Boehringer Ingelheim Pharma Novel medicaments for inhalation.
US7244415B2 (en) 2002-03-28 2007-07-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg HFA suspension formulations of an anhydrate
DE10214263A1 (en) * 2002-03-28 2003-10-16 Boehringer Ingelheim Pharma HFA suspension formulations containing an anticholinergic
US7311894B2 (en) 2002-03-28 2007-12-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg HFA suspension formulations containing an anticholinergic
DE10256080A1 (en) * 2002-11-29 2004-06-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Combination medicinal product for inhalation containing tiotropium
US7250426B2 (en) 2002-11-29 2007-07-31 Boehringer Ingelheim Pharma Gmbh & Co Kg Tiotropium-containing pharmaceutical combination for inhalation
EP1575588A1 (en) * 2002-12-16 2005-09-21 Boehringer Ingelheim Pharma GmbH & Co.KG Tiotropium containing hfc solution formulations
DE10351663A1 (en) * 2002-12-20 2004-07-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Stable, accurately dosable inhalable powder medicament for treating asthma or chronic obstructive pulmonary disease, containing tiotropium, specific form of salmeterol xinafoate and auxiliary
DE10345065A1 (en) * 2003-09-26 2005-04-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Aerosol formulation for inhalation containing an anticholinergic
CA2544348A1 (en) * 2003-11-03 2005-05-12 Boehringer Ingelheim International Gmbh Method for producing tiotropium salts, tiotropium salts and pharmaceutical formulations, containing the same
PL2083007T3 (en) * 2003-11-03 2013-09-30 Boehringer Ingelheim Int Tiotropium salts, method for creating same and medicinal formulations containing same
WO2005115465A1 (en) * 2004-05-31 2005-12-08 Almirall Prodesfarma S.A. Combinations comprising antimuscarinic agents and pde4 inhibitors
ES2257152B1 (en) * 2004-05-31 2007-07-01 Laboratorios Almirall S.A. COMBINATIONS THAT INCLUDE ANTIMUSCARINIC AGENTS AND BETA-ADRENERGIC AGONISTS.
NZ563596A (en) 2005-05-02 2011-01-28 Boehringer Ingelheim Int Crystalline form of tiotropium bromide anhydrate
EP1959942A1 (en) * 2005-08-06 2008-08-27 Boehringer Ingelheim International GmbH Method for the treatment of dyspnea comprising combined administration of tiotropium salts and salts of salmeterol
ES2298049B1 (en) 2006-07-21 2009-10-20 Laboratorios Almirall S.A. PROCEDURE FOR MANUFACTURING BROMIDE OF 3 (R) - (2-HIDROXI-2,2-DITIEN-2-ILACETOXI) -1- (3-PHENOXIPROPIL) -1-AZONIABICICLO (2.2.2) OCTANO.
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100598A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
US20120220557A1 (en) * 2011-02-17 2012-08-30 Chiesi Farmaceutici S.P.A. Liquid propellant-free formulation comprising an antimuscarinic drug
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
WO2013127738A1 (en) * 2012-02-28 2013-09-06 Boehringer Ingelheim International Gmbh Novel propellant-gas-containing tiotropium formulation
WO2015065222A1 (en) * 2013-10-28 2015-05-07 Шолекс Девелопмент Гмбх Pharmaceutical inhaled drug with micronized tiotropium bromide as active ingredient for the treatment of bronchial asthma and chronic obstructive pulmonary disease and method for producing same
TW201835041A (en) 2017-02-17 2018-10-01 印度商托仁特生技有限公司 Compounds with Beta-Adrenergic Agonist and Antimuscarinic Activity
WO2019142214A1 (en) * 2018-01-19 2019-07-25 Cipla Limited Pharmaceutical composition comprising tiotropium for inhalation
CN116196298A (en) * 2018-07-26 2023-06-02 四川海思科制药有限公司 Aerosol pharmaceutical composition containing glycopyrronium salt and preparation method and application thereof
WO2020019952A1 (en) * 2018-07-26 2020-01-30 四川海思科制药有限公司 Aerosol pharmaceutical composition containing glycopyrrolate salt and indacaterol salt, preparation method therefor, and uses thereof
US12042514B2 (en) 2020-05-01 2024-07-23 Tygrus, LLC Therapeutic material with low pH and low toxicity active against at least one pathogen for addressing patients with respiratory illnesses
US11642372B2 (en) 2020-05-01 2023-05-09 Tygrus, LLC Therapeutic material with low pH and low toxicity active against at least one pathogen for addressing patients with respiratory illnesses
WO2022119661A1 (en) * 2020-12-04 2022-06-09 Tygrus, LLC THERAPEUTIC MATERIAL WITH LOW pH AND LOW TOXICITY ACTIVE AGAINST AT LEAST ONE PATHOGEN FOR ADDRESSING PATIENTS WITH RESPIRATORY ILLNESSES
US11826382B2 (en) 2020-05-01 2023-11-28 Tygrus, LLC Therapeutic material with low pH and low toxicity active against at least one pathogen for addressing patients with respiratory illnesses

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2234266T3 (en) * 1998-07-24 2005-06-16 Jago Research Ag MEDICAL FORMULATIONS FOR AEROSOLS.
DE19835346A1 (en) * 1998-08-05 2000-02-10 Boehringer Ingelheim Pharma Two-part capsule for pharmaceutical preparations for powder inhalers
DE19847970A1 (en) * 1998-10-17 2000-04-20 Boehringer Ingelheim Pharma Stable concentrated liquid formulation of inhalable drug, e.g. formoterol or salbutamol, in solution or suspension medium, used after dilution for treatment of respiratory disorders by inhalation
DE19847971A1 (en) * 1998-10-17 1999-09-02 Schiering Filter fire occurrence prevention method
DE19921693A1 (en) * 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Pharmaceutical composition for treating respiratory disorders, e.g. asthma, comprises combination of anticholinergic and beta-mimetic agents having synergistic bronchospasmolytic activity and reduced side-effects
DE19961300A1 (en) * 1999-12-18 2001-06-21 Asta Medica Ag Storage system for medicinal products in powder form and inhaler equipped with them

Also Published As

Publication number Publication date
NO20032111L (en) 2003-07-08
SK7412003A3 (en) 2003-10-07
CN1678318A (en) 2005-10-05
SI1514546T1 (en) 2007-10-31
ES2287629T3 (en) 2007-12-16
SI1335728T1 (en) 2005-08-31
JP4282594B2 (en) 2009-06-24
BR0115226A (en) 2003-10-07
DK1514546T3 (en) 2007-09-24
ZA200302921B (en) 2004-04-19
EP1514546B1 (en) 2007-05-23
MXPA03004164A (en) 2005-08-16
AU2007202303B2 (en) 2010-01-21
JP2005068163A (en) 2005-03-17
EA200300503A1 (en) 2004-12-30
IL155718A0 (en) 2003-11-23
KR100940752B1 (en) 2010-02-11
DE50112535D1 (en) 2007-07-05
RS20090105A (en) 2009-07-15
EP1335728B1 (en) 2005-03-23
EE200300228A (en) 2003-10-15
EP1514546A1 (en) 2005-03-16
UA74853C2 (en) 2006-02-15
PL365989A1 (en) 2005-01-24
EP1808174A1 (en) 2007-07-18
DE10056104A1 (en) 2002-05-23
AU2007202303A1 (en) 2007-06-14
DE50105729D1 (en) 2005-04-28
AU2791002A (en) 2002-05-21
JP2004513146A (en) 2004-04-30
PT1335728E (en) 2005-05-31
IL155718A (en) 2010-06-30
ATE362761T1 (en) 2007-06-15
HRP20030378A2 (en) 2005-04-30
EP1335728A1 (en) 2003-08-20
BG107781A (en) 2004-06-30
DK1335728T3 (en) 2005-04-18
JP4282322B2 (en) 2009-06-17
RS50286B (en) 2009-09-08
SK286939B6 (en) 2009-07-06
NZ526400A (en) 2005-09-30
EA007904B1 (en) 2007-02-27
ES2240549T3 (en) 2005-10-16
AU2002227910B2 (en) 2007-03-01
WO2002038154A1 (en) 2002-05-16
HUP0301447A3 (en) 2007-10-29
HUP0301447A2 (en) 2003-10-28
PT1514546E (en) 2007-06-15
SG167657A1 (en) 2011-01-28
SK286950B6 (en) 2009-08-06
PL205330B1 (en) 2010-04-30
KR20080079701A (en) 2008-09-01
YU35503A (en) 2006-05-25
KR100886094B1 (en) 2009-02-27
KR20030065509A (en) 2003-08-06
CA2429012A1 (en) 2002-05-16
CY1106774T1 (en) 2012-05-23
CZ20031444A3 (en) 2003-08-13
ECSP034571A (en) 2003-06-25
ATE291428T1 (en) 2005-04-15

Similar Documents

Publication Publication Date Title
NO20032111D0 (en) New drug compositions based on tiotropium salts and on salmeterol salts
RS50269B (en) NOVEL MEDICAMENT COMPOSITIONS, BASED ON ANTICHOLINERGICALLY EFFECTIVE COMPOUNDS AND β-MIMETICS
IS8230A (en) Substitute 2-aminotetraline for use in the treatment of depression
NO20022334D0 (en) New composition and application
TW200606147A (en) Indolyl derivatives as liver-X-receptor modulators
RS50814B (en) Tartarate salts of 5,8,14-triazatetracyclo(10.3.1.02,11.04,9 )-hexadeca-2(11)3,5,7,9-pentaene and pharmaceutical compositions thereof
NO20045486L (en) New compounds and their use
AR018197A1 (en) PIPERIDINE COMPOUNDS, A PROCEDURE FOR THE PREPARATION, A COMPOSITION AND USE OF THE SAME FOR THE PREPARATION OF A MEDICINAL PRODUCT
ATE397605T1 (en) NEBIVOLOL AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS, PRODUCTION PROCESS AND PHARMACEUTICAL COMPOSITIONS OF NEBIVOLOL
NO20075022L (en) (7- (2- (4- (3-trifluoromethylphenyl) -1,2,3,6-tetrahydropyrid-1-yl) ethyl) isoquinoline besylate salt, preparation and therapeutic uses thereof
MY134167A (en) Biphenylcarboxamides useful as lipid lowering agents
AU4397501A (en) Process of making racemic bupivacaine's enantiomers, levobupivacaine's pharmaceutical compositions, levobupivacaine's pharmaceutical compositions formulated on its free base form or its pharmaceutical acceptable salts and use of levobupivacaine's pharmaceutical compositions formulated on its free base form
BR0210912A (en) Compounds and compositions as cathepsin inhibitors
GEP20094801B (en) Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof
AU2001290480A1 (en) Cyclized benzamide neurokinin antagonists for use in therapy
NO20070974L (en) Substituted N-acyl-2-aminothiazoles
TW200517146A (en) Novel composition
HK1086819A1 (en) 2-(butyl-1-sulfonylamino)-n-(1(r)-(6-methoxy-pyridin-3-yl)-propyl)-benzamid, the use thereof in the form of drug an pharmaceutical preparations containing said compound
PE20020525A1 (en) COMPOSITIONS INCLUDING TIOTROPE SALTS AND ANTIHISTAMINE AGENTS
SE0102058D0 (en) New Salts II
NO20000199D0 (en) Medications containing polyhydroxybutylpyrazines, new polyhydroxybutylpyrazines and their preparation
SE0102809D0 (en) Novel compounds
DE60300683D1 (en) Prucalopride NOXIDE
IT1318650B1 (en) 1,3-DIOSSOLANS WITH ANTI-TOXIC ACTIVITY.
ECSP045014A (en) NEW COMPOUNDS

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application